Format

Send to

Choose Destination
Trends Pharmacol Sci. 2014 Mar;35(3):155-61. doi: 10.1016/j.tips.2014.01.004. Epub 2014 Feb 17.

The pathophysiology and pharmacology of hepcidin.

Author information

1
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
2
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address: enemeth@mednet.ucla.edu.

Abstract

Inappropriate production of the iron-regulatory hormone hepcidin contributes to the pathogenesis of common iron disorders. Absolute or relative deficiency of hepcidin causes iron overload in hereditary hemochromatosis and iron-loading anemias. Elevated hepcidin causes iron restriction in inflammatory conditions including autoimmune disease, critical illness, some cancers, and chronic kidney disease. Multiple agents targeting hepcidin and its regulators are under development as novel therapeutics for iron disorders. This review summarizes hepcidin biology and discusses the current landscape for hepcidin-targeting therapeutic strategies.

KEYWORDS:

anemia; ferroportin; iron disorders; iron overload

PMID:
24552640
PMCID:
PMC3978192
DOI:
10.1016/j.tips.2014.01.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center